Bacteriocin production in vancomycin-resistant and vancomycin-susceptible Enterococcus isolates of different origins.

  1. Del Campo, R. 1
  2. Tenorio, C. 1
  3. Jiménez-Díaz, R. 1
  4. Rubio, C. 1
  5. Gómez-Lus, R. 1
  6. Baquero, F. 1
  7. Torres, C. 1
  1. 1 Universidad de La Rioja

    Universidad de La Rioja

    Logroño, España


Antimicrobial Agents and Chemotherapy

ISSN: 0066-4804

Any de publicació: 2001

Volum: 45

Número: 3

Pàgines: 905-912

Tipus: Article

DOI: 10.1128/AAC.45.3.905-912.2001 PMID: 11181378 SCOPUS: 2-s2.0-0035119499 WoS: WOS:000167134800041 GOOGLE SCHOLAR

Altres publicacions en: Antimicrobial Agents and Chemotherapy

Arxiu institucional: lock_openAccés obert editor


Cites rebudes

  • Cites en Scopus: 66 (09-09-2023)
  • Citas en Web of Science: 64 (07-09-2023)
  • Cites en Dimensions: 60 (30-03-2023)

JCR (Journal Impact Factor)

  • Any 2001
  • Factor d'impacte de la revista: 4.562
  • Factor d'impacte sense autocites: 3.599
  • Article influence score: 0.0
  • Quartil major: Q1
  • Àrea: PHARMACOLOGY & PHARMACY Quartil: Q1 Posició en l'àrea: 12/186 (Edició: SCIE)
  • Àrea: MICROBIOLOGY Quartil: Q1 Posició en l'àrea: 9/81 (Edició: SCIE)

SCImago Journal Rank

  • Any 2001
  • Impacte SJR de la revista: 2.334
  • Quartil major: Q1
  • Àrea: Infectious Diseases Quartil: Q1 Posició en l'àrea: 10/163
  • Àrea: Pharmacology (medical) Quartil: Q1 Posició en l'àrea: 2/183
  • Àrea: Pharmacology Quartil: Q1 Posició en l'àrea: 9/296


(Dades actualitzats a data de 30-03-2023)
  • Cites totals: 60
  • Cites recents: 3
  • Relative Citation Ratio (RCR): 1.7
  • Field Citation Ratio (FCR): 3.78


Bacteriocin production was determined for 218 Enterococcus isolates (Enterococcusfaecalis [93] and E. faecium [125]) obtained from different origins (human clinical samples [87], human fecal samples [78], sewage [28], and chicken samples [25]) and showing different vancomycin susceptibility patterns (vancomycin resistant, all of them vanA positive [56], and vancomycin susceptible [162]). All enterococcal isolates were randomly selected except for the vancomycin-resistant ones. A total of 33 isolates of eight different bacterial genera were used as indicators for bacteriocin production. Forty-seven percent of the analyzed enterococcal isolates were bacteriocin producers (80.6% of E. faecalis and 21.6% of E. faecium isolates). The percentage of bacteriocin producers was higher among human clinical isolates (63.2%, 81.8% of vancomycin-resistant isolates and 60.5% of vancomycin-susceptible ones) than among isolates from the other origins (28 to 39.3%). Only one out of the 15 vancomycin-resistant isolates from human fecal samples was a bacteriocin producer, while 44.4% of fecal vancomycin-susceptible isolates were. The bacteriocin produced by the vanA-containing E. faecium strain RC714, named bacteriocin RC714, was further characterized. This bacteriocin activity was cotransferred together with the vanA genetic determinant to E. faecalis strain JH2-2. Bacteriocin RC714 was purified to homogeneity and its primary structure was determined by amino acid sequencing, showing an identity of 88% and a similarity of 92% with the previously described bacteriocin 31 from E. faecalis YI717. The presence of five different amino acids in bacteriocin RC714 suggest that this could be a new bacteriocin. The results obtained suggest that the epidemiology of vancomycin resistance may be influenced by different factors, including bacteriocin production.